Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Human chorionic gonadotropin therapy in hypogonadic severe-oligozoospermic men and its effect on semen parameters

  • Received : 2021.06.07
  • Accepted : 2021.11.13
  • Published : 2022.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This study aimed to evaluate whether human chorionic gonadotropin (hCG) therapy is beneficial for improving semen parameters and clinical hypogonadism symptoms in hypogonadic oligozoospermic or severe oligozoospermic men with low or borderline testosterone levels. Methods: A weekly dose of 250 ㎍ (equivalent to approximately 6,500 IU) of hCG was administered subcutaneously for 3-6 months to 56 hypogonadic oligozoospermic or severe oligozoospermic men. Semen, biochemical, and genetic analyses were performed before the start of treatment followed by analyzing semen parameters every 3 months after the start of therapy. We grouped participants into responders and non-responders depending on positive changes in semen parameters. Results: Out of 56 men, 47 (83.93%) responded, while 9 (16.07%) did not. Upon statistical analysis, it was found that age did not affect the overall outcomes (p=0.292); however, men with higher body mass index (BMI; 28.09±3.48 kg/m2) showed better outcomes than those with low BMI (25.33±3.06 kg/m2) (p=0.042). The duration of therapy (in months) was higher in non-responders than in responders (p=0.020). We found significant improvements in sperm concentration (p=0.006) and count (p=0.005) after 3 months of therapy. Sperm motility and progressive motility were also found to be higher in responders, but did not show statistically significant changes. Conclusion: We conclude that hCG therapy can be beneficial in men with hypogonadic oligozoospermia or severe oligozoospermia.

Keywords

Acknowledgement

Rajender Singh is thankful to the Council of Scientific and Industrial Research (CSIR) for funding under MLP0113-DeMID.

References

  1. Waseem AS, Singh V, Makker GC, Trivedi S, Mishra G, Singh K, et al. AZF deletions in Indian populations: original study and meta-analyses. J Assist Reprod Genet 2020;37:459-69. https://doi.org/10.1007/s10815-019-01661-0
  2. Kamel RM. Management of the infertile couple: an evidence-based protocol. Reprod Biol Endocrinol 2010;8:21. https://doi.org/10.1186/1477-7827-8-21
  3. Silva FR, Leite LD, Wassermann GF. Rapid signal transduction in Sertoli cells. Eur J Endocrinol 2002;147:425-33. https://doi.org/10.1530/eje.0.1470425
  4. Ramaswamy S, Weinbauer GF. Endocrine control of spermatogenesis: role of FSH and LH/ testosterone. Spermatogenesis 2015;4:e996025. https://doi.org/10.1080/21565562.2014.996025
  5. Carnegie C. Diagnosis of hypogonadism: clinical assessments and laboratory tests. Rev Urol 2004;6 Suppl 6:S3-8.
  6. Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol 2012;2012:625434. https://doi.org/10.1155/2012/625434
  7. Khera M, Broderick GA, Carson CC 3rd, Dobs AS, Faraday MM, Goldstein I, et al. Adult-onset hypogonadism. Mayo Clin Proc 2016;91:908-26. https://doi.org/10.1016/j.mayocp.2016.04.022
  8. Lo EM, Rodriguez KM, Pastuszak AW, Khera M. Alternatives to testosterone therapy: a review. Sex Med Rev 2018;6:106-13. https://doi.org/10.1016/j.sxmr.2017.09.004
  9. Lee JA, Ramasamy R. Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. Transl Androl Urol 2018;7(Suppl 3):S348-52. https://doi.org/10.21037/tau.2018.04.11
  10. Rohrmann S, Platz EA, Selvin E, Shiels MS, Joshu CE, Menke A, et al. The prevalence of low sex steroid hormone concentrations in men in the Third National Health and Nutrition Examination Survey (NHANES III). Clin Endocrinol (Oxf) 2011;75:232-9. https://doi.org/10.1111/j.1365-2265.2011.04043.x
  11. World Health Organization. WHO laboratory manual for the examination and processing of human semen. Geneva: World Health Organization; 2021.
  12. Krausz C, Hoefsloot L, Simoni M, Tuttelmann F, European Academy of Andrology; European Molecular Genetics Quality Network. EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: state-of-the-art 2013. Andrology 2014;2:5-19. https://doi.org/10.1111/j.2047-2927.2013.00173.x
  13. Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab 2009;94:801-8. https://doi.org/10.1210/jc.2008-1648
  14. Whitten SJ, Nangia AK, Kolettis PN. Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate. Fertil Steril 2006;86:1664-8. https://doi.org/10.1016/j.fertnstert.2006.05.042
  15. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013;173:1465-6. https://doi.org/10.1001/jamainternmed.2013.6895
  16. Andrabi SW, Saini P, Joshi M, Mehta P, Makker GC, Mishra G, et al. HCG therapy in azoospermic men with lower or borderline testosterone levels and the prognostic value of Y-deletion analysis in its outcome. Andrologia 2022;54:e14251.